CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

Phase 4

Completed

• Conditions: Infertility
• Interventions: Drug: GONAL f® prefilled pen

• Registration Number: NCT00829244
• Lead Sponsor: Merck KGaA, Darmstadt, Germany

Brief Summary

The overall objective of this trial is to compare the ovarian response in assisted reproductive technology (ART) subjects administered GONAL f® according to the 'Consistency in recombinant follicle stimulating hormone \[r-FSH\] starting doses for individualized treatment' (CONSORT) calculator versus given a standard GONAL f® dose of 150 International Unit (IU) per day.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2009-01-22
• Study First Submitted QC: 2009-01-23
• Study First Posted: 2009-01-26
• Primary Completion: 2010-01
• Study Completion: 2010-01
• Results First Submitted: 2012-06-01
• Results First Submitted QC: 2012-08-07
• Results First Posted: 2012-09-07
• Status Verified: 2014-01
• Last Update Submitted: 2014-01-20
• Last Update Posted: 2014-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

1. Female subjects justifying an in-vitro fertilization (IVF)/embryo transfer (ET) treatment
2. Have a male partner with semen analysis within the past 6 months prior to randomization considered adequate to proceed with regular insemination or intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If these criteria are not met, the subject can only be entered if donor sperm will be used
3. Between her 18th and 35th birthday (35 not included) at the time of the randomization visit
4. Body mass index (BMI) lower than 30 kilogram per square meter (kg/m^2) where the BMI is calculated according to the formula
5. Have a regular spontaneous ovulatory menstrual cycle between 21 and 35 days in length
6. Have an early follicular phase (Day 2-4) serum level of basal FSH lower than or equal to 12 International Unit per Liter (IU/L) measured in the center's local laboratory during the screening period (i.e. within 2 months prior to down-regulation start)
7. Presence of both ovaries
8. Normal uterine cavity, which in the investigator's opinion is compatible with pregnancy
9. Have a negative cervical papanicolaou (PAP) test within the last 6 months prior to randomization
10. Have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotropin releasing hormone (GnRH) agonist therapy
11. Willing and able to comply with the protocol for the duration of the trial
12. Have given written informed consent, prior to any trial-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care

Exclusion Criteria

1. Have greater than or equal to 2 previous ART cycles with a poor response to gonadotrophin stimulation (defined as lower than or equal to 5 mature follicles and/or lower than or equal to 3 oocytes collected) or have greater than or equal to 2 previous ART cycles with a hyper response (defined as greater than or equal to 25 oocytes retrieved)
2. Any medical condition, which in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the subject in question should be discussed with Merck Serono's Medical responsible
3. Have previous severe ovarian hyperstimulation syndrome (OHSS)
4. Polycystic ovary syndrome (PCOS; Rotterdam criteria) to reduce the risk of the occurrence of OHSS
5. Presence of endometriosis requiring treatment
6. Uterine myoma requiring treatment
7. Any contraindication to being pregnant and/or carrying a pregnancy to term
8. Extra-uterine pregnancy within the last 3 months prior to screening
9. History of 3 or more miscarriages (early or late miscarriages) due to any cause
10. Tumors of the hypothalamus and pituitary gland
11. Ovarian enlargement or cyst of unknown etiology
12. Ovarian, uterine or mammary cancer
13. A clinically significant systemic disease
14. Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus in the trial subject or her male partner,
15. Abnormal gynecological bleeding of undetermined origin
16. Known allergy or hypersensitivity to human gonadotrophin preparations,
17. Any active substance abuse or history of drug medication or alcohol abuse in the past 5 years prior to the screening visit
18. Entered previously into this trial or simultaneous participation in another clinical trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CONSORT Dosing	GONAL f® prefilled pen	GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
Standard Dosing	GONAL f® prefilled pen	GONAL-f® at a standard dose of 150 IU per day

Primary Outcome Measures

Name	Time	Method
Number of Oocytes Retrieved Per Participant	34-38 hours post-recombinant human choriogonadotropin (hCG) (OPU)	Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Biochemical Pregnancies	Start of treatment until Day 15-20 Post-hCG	Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum and that does not develop into a clinical pregnancy.
Total GONAL-f® Dose	Start of treatment until end of stimulation cycle (approximately 28 days)
Mean GONAL-f® Daily Dose	Start of treatment until end of stimulation cycle (approximately 28 days)
Total Number of GONAL-f® Stimulation Treatment Days	Start of treatment until end of stimulation cycle (approximately 28 days)
Number of Participants With Cancelled Cycles Due to Excessive or Inadequate Response to Treatment	Start of treatment until Day 15-20 post-hCG	Number of participants with cancelled cycles due to excessive or inadequate response was evaluated. An excessive response: greater than or equal to 25 oocytes which could put the participant at risk of OHSS; An inadequate response: defined as 3 or less follicles of greater than or equal to 12 millimeter (mm) developing following at least 7 days of GONAL-f® treatment.
Number of Participants With Fetal Sacs and Fetal Hearts	Day 35-42 Post-hCG	Number of participants with fetal sacs and fetal hearts (with activity) as seen on an ultrasound scan to confirm clinical pregnancy.
Implantation Rate	Day 35-42 Post-hCG	Implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.
Number of Participants With Multiple Pregnancies	Day 35-42 Post-hCG	Multiple pregnancy was defined as 2 or more fetal hearts with activity.
Serum Progesterone (P4) Levels	End of stimulation cycle (approximately 28 days)
Pregnancy Outcome - Number of Participants With Pregnancy and Their Outcome	up to 9 month (following the end of treatment)	Pregnancy outcomes are live outcome (live infant) and non-live outcome (non-live infant) or unknown outcome (subject lost to follow-up).
Percentage of Participants With Clinical Pregnancy	Day 35-42 Post-hCG	Clinical pregnancy is defined by the number of sacs and hearts with activity per ultrasound scan performed on Day 35-42 post-hCG.
Number of Participants With OHSS	Start of treatment until Day 15-20 Post-hCG	OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

Trial Locations

Locations (1)

Research Site; 🇨🇭 Geneva, Switzerland